Key Business Developments Financial Results for Quarter and Year Ended December ... Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full ... Centered in the US, Legend is building an end-to-end cell therapy company by expanding ...